These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33538911)

  • 1. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome.
    Holle J; Habbig S; Gratopp A; Mauritsch A; Müller D; Thumfart J
    Pediatr Nephrol; 2021 May; 36(5):1311-1315. PubMed ID: 33538911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical hemolytic uremic syndrome.
    Loirat C; Frémeaux-Bacchi V
    Orphanet J Rare Dis; 2011 Sep; 6():60. PubMed ID: 21902819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M; Detaille T; Godefroid N
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):e459-e462. PubMed ID: 30933023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].
    Reis S; Ramos D; Cordinhã C; Gomes C
    Acta Med Port; 2019 Oct; 32(10):673-675. PubMed ID: 31625881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
    Haskin O; Falush Y; Davidovits M
    Pediatr Nephrol; 2019 Dec; 34(12):2601-2604. PubMed ID: 31520126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA; Rahim KA; Faqeehi HY; Alanazi A
    Kidney Blood Press Res; 2020; 45(6):939-954. PubMed ID: 33238263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
    Barlas UK; Kıhtır HS; Goknar N; Ersoy M; Akcay N; Sevketoglu E
    Pediatr Nephrol; 2018 Jun; 33(6):1093-1096. PubMed ID: 29558000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-enteropathic hemolytic uremic syndrome: causes and short-term course.
    Constantinescu AR; Bitzan M; Weiss LS; Christen E; Kaplan BS; Cnaan A; Trachtman H
    Am J Kidney Dis; 2004 Jun; 43(6):976-82. PubMed ID: 15168377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.
    Ahlenstiel-Grunow T; Hachmeister S; Bange FC; Wehling C; Kirschfink M; Bergmann C; Pape L
    Nephrol Dial Transplant; 2016 Jul; 31(7):1114-21. PubMed ID: 27190382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes.
    Konopásek P; Zieg J
    Pediatr Nephrol; 2023 Dec; 38(12):4209-4215. PubMed ID: 37306721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome.
    Scobell RR; Kaplan BS; Copelovitch L
    Pediatr Nephrol; 2020 Sep; 35(9):1585-1591. PubMed ID: 31515631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Brocklebank V; Johnson S; Sheerin TP; Marks SD; Gilbert RD; Tyerman K; Kinoshita M; Awan A; Kaur A; Webb N; Hegde S; Finlay E; Fitzpatrick M; Walsh PR; Wong EKS; Booth C; Kerecuk L; Salama AD; Almond M; Inward C; Goodship TH; Sheerin NS; Marchbank KJ; Kavanagh D
    Kidney Int; 2017 Nov; 92(5):1261-1271. PubMed ID: 28750931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.